ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
Theriva Biologics reports positive data from investigator sponsored phase 1 trial of intravitreal VCN-01 in paediatric patients with refractory retinoblastoma
“Phase 1 trial in collaboration with Sant Joan de D©u-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee“ “Safety and clinical outcomes...
“ Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft“ “ The observed synergy emphasizes VCN-01's...
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
“ The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal...
ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva„ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
Theriva„¢ Biologics to Participate in the BIO-Europe Spring Conference
ROCKVILLE, Md., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Theriva„¢ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
Theriva to Participate in the B. Riley Securities Annual Oncology Conference